Study on the Effect of Hyperbaric Oxygen Intervention on Relieving Sports Fatigue of Sailors
- Research Purpose Intensive training often causes autonomic nerve imbalance, poor microcirculation and slow fatigue recovery in elite sailing athletes. This study adopted 1.3 ATA mild hyperbaric oxygen with 28% oxygen concentration for a 6-week intervention. It aimed to explore whether mild hyperbaric oxygen can improve athletes' autonomic nerve function, microcirculation and fatigue-related biochemical indicators. Meanwhile, it intended to estimate the effect size, provide basis for future large-scale formal trials, and optimize fatigue recovery strategies for sailing athletes and other endurance athletes.
Study Population A total of 16 elite male sailing athletes were enrolled and randomly divided into two groups with 8 participants in each group.
Inclusion criteria: aged over 18 years; holding national first-class athlete certificate or above; participating in systematic sailing training at least 5 times a week with more than 5 years of professional training experience.
Those with cardiovascular diseases, absolute contraindications to hyperbaric oxygen, training suspension due to injury and other ineligible conditions were excluded.
- Primary Outcome Measures Autonomic nerve function: Heart rate variability (HRV) indicators were tested to observe whether hyperbaric oxygen balances sympathetic and parasympathetic nerves and relieves training-induced autonomic disorder.
Microcirculation function: Measured muscle microcirculation blood flow velocity, capillary perfusion and thermal stimulation microvascular reserve capacity to evaluate the improvement of peripheral blood circulation.
Fatigue and biochemical biomarkers:
Routine blood indexes: red blood cell, hemoglobin, white blood cell; Exercise injury and metabolic indexes: creatine kinase (CK), blood urea nitrogen (BUN), testosterone and cortisol; Oxidative stress indexes: malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), to assess the body's oxidation-antioxidant status, inflammation level and fatigue recovery degree.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: jin yu
- Telefonnummer: +86 18101732823
- E-post: 759559257@qq.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Male elite sailing athletes aged 18-35 years
- Holding a national first-class athlete certificate or above
- With at least 5 years of professional sailing training experience
- Engaging in regular sailing training ≥ 5 times per week
- Voluntarily sign the informed consent form
Exclusion Criteria:
- - Presence of cardiovascular, respiratory, or neurological diseases
- Absolute contraindications to hyperbaric oxygen therapy
- Current injury or illness requiring medical treatment or training suspension
- Use of any medications or supplements that may affect fatigue recovery or autonomic function
- Participation in other concurrent recovery interventions during the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Mild Hyperbaric Oxygen Intervention Group
|
Participants receive mild hyperbaric oxygen therapy (mHBOT) in a hyperbaric chamber at 1.3 atmospheres absolute (ATA) with 28% oxygen concentration, for 60 minutes per session, 5 sessions per week over 6 weeks.
All participants continue their standard sailing training regimen throughout the study.
|
|
Ingen inngripen: Control Group (No Hyperbaric Oxygen)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in Heart Rate Variability (HRV)
Tidsramme: Baseline (Week 0), Post-intervention (Week 6)
|
Baseline (Week 0), Post-intervention (Week 6)
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- LLSC20250004
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .